UBS O'Connor’s Nuvation Bio NUVB Stock Holding History

UBS O'Connor’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-282,464	Closed	-$551K	–	399
2025 Q2	$551K	Sell	282,464 -309,655	-52%	-$645K	0.01%	268
2025 Q1	$1.04M	Buy	+592,119	New	+$1.35M	0.02%	181

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

UBS O'Connor's NUVB Position: Q3 2025 in Review

UBS O'Connor sold out of Nuvation Bio (NUVB) in Q3 2025, closing a stake of 282,464 shares — an estimated $551K sold.

UBS O'Connor first reported a position in NUVB in Q1 2025 and held it in 2 quarters. The position peaked at $1.04M in Q1 2025. 203 funds tracked by Wall St. Rank hold NUVB as of Q3 2025.

UBS O'Connor reported no remaining Nuvation Bio position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 282,464 Nuvation Bio shares in Q3 2025, an estimated $551K.
UBS O'Connor first reported a position in Nuvation Bio in Q1 2025 and held it in 2 quarters.
UBS O'Connor's Nuvation Bio position peaked at $1.04M in Q1 2025.
203 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.